Literature DB >> 30804153

Palonosetron on Days 1 and 5 Versus Granisetron Daily (Days 1-5) in Germ Cell Tumour Therapy.

Yusuke Shimura1,2, Kouji Izumi3, Shingo Itai1, Hiroaki Iwamoto4, Hiroshi Yaegashi4, Yukio Suga2, Tsutomu Shimada1, Atsushi Mizokami4, Yoshimichi Sai1.   

Abstract

BACKGROUND/AIM: The control of chemotherapy-induced nausea and vomiting during bleomycin, etoposide, and cisplatin (BEP) treatment is important for maintaining treatment intensity. The effects of palonosetron and granisetron were compared in BEP chemotherapy. PATIENTS AND METHODS: The administration of palonosetron on days 1 and 5 (Pal method) and granisetron daily (days 1-5, Gra method) were compared in terms of their efficacy and cost-effectiveness.
RESULTS: Additional rescue antiemetic agents were used in 15 of 32 and 30 of 30 cycles in the Pal and Gra method groups, respectively (p<0.05). The complete response rate, defined as no vomiting and no rescue agent usage, in each cycle, was 50% and 0% in the Pal and Gra method groups, respectively (p<0.05). The average cost of antiemetic agents in a cycle was 50,759 and 54,555 yen in the Pal and Gra method groups, respectively (p<0.05).
CONCLUSION: The Pal method may be the standard method in BEP. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Germ cell tumour; chemotherapy-induced nausea and vomiting; granisetron; palonosetron

Mesh:

Substances:

Year:  2019        PMID: 30804153      PMCID: PMC6506324          DOI: 10.21873/invivo.11522

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  Treatment at an Inexperienced Center Suggests Worse Prognosis of Metastatic Germ Cell Tumors.

Authors:  Hiroshi Yaegashi; Kouji Izumi; Suguru Kadomoto; Hiroaki Iwamoto; Masashi Iijima; Shohei Kawaguchi; Takahiro Nohara; Kazuyoshi Shigehara; Yoshifumi Kadono; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2021-03-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.